57例脂质性先天性肾上腺增生症患者的临床特征:非经典型诊断标准的重新审视
日本多中心横断面队列研究于2017年12月1日纳入57例脂质性先天性肾上腺增生症(LCAH)患者,中位年龄23.7岁。按新标准将患者分为经典型43例(75.4%)、非经典型11例(19.3%)和未分类3例(5.3%)。经典型诊断年龄显著早于非经典型(中位0.0 vs 4.0年),STAR-Arg272Cys或-Met225Thr仅见于非经典型(8/11,72.7%)。
要点
- 非经典型LCAH定义:XY核型Quigley 1级、无失盐发作或无需氟氢可的松、或原发性肾上腺功能不全起病≥1岁。
- 经典型LCAH诊断年龄显著早于非经典型(中位0.0 vs 4.0年)。
- STAR-Arg272Cys或-Met225Thr仅见于非经典型(8/11,72.7%)。
核心结论
- 研究展示了日本非经典型与经典型LCAH的相对比例及临床和分子特征。
- 该非经典型LCAH标准与所有已发表病例及本研究中描述外生殖器男性化、盐皮质激素产生能力和PAI起病的病例相符。
研究设计与样本
- 日本多中心横断面队列研究,于2017年12月1日进行。
- 纳入57例LCAH患者,中位年龄23.7岁(范围0.0-47.5岁)。
- 53例符合LCAH确诊标准,4例符合可能诊断标准。
主要发现
- 经典型LCAH 43例(75.4%),非经典型11例(19.3%),未分类3例(5.3%)。
- 所有经典型患者和7/11例(63.6%)非经典型患者接受氟氢可的松治疗。
- 经典型诊断年龄显著早于非经典型(中位0.0 vs 4.0年)。
- STAR-Arg272Cys或-Met225Thr仅见于非经典型(8/11,72.7%)。
关键数值与推荐
- 非经典型LCAH定义为满足以下任一条件:XY核型Quigley 1级;无失盐发作或无需氟氢可的松;原发性肾上腺功能不全起病年龄≥1岁。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Lipoid congenital adrenal hyperplasia (LCAH) is caused by mutations in STAR. Classic (CLCAH) and nonclassic (NCLCAH) forms were reported as total and partial deficiencies, respectively, of adrenal and gonadal steroid hormones. The rarity of LCAH has precluded large-scale epidemiological and clinical investigations. OBJECTIVE: To determine the epidemiological and clinical characteristics of 2 forms of LCAH. DESIGN: A multicenter cross-sectional cohort study in Japan on December 1, 2017. PARTICIPANTS: Fifty-seven patients with LCAH (median age, 23.7 years; range, 0.0-47.5 years). MAIN OUTCOME MEASURES: Patient demographics, STAR genotype, Quigley grade, endocrinological and imaging data, treatment, and prognosis. RESULTS: Fifty-three and 4 patients fulfilled definite and probable diagnostic criteria for LCAH, respectively. When NCLCAH was defined as either Quigley grade 1 in XY karyotype, no episode of salt losing or requirement of fludrocortisone, or onset of primary adrenal insufficiency (PAI) at 1 year or older, patients were divided into groups of 43 patients with CLCAH (75.4%), 11 with NCLCAH (19.3%), and 3 with unclassified LCAH (5.3%). All of the patients with CLCAH and 7/11 NCLCAH (63.6%) were treated with fludrocortisone. CLCAH was diagnosed at a significantly younger age than NCLCAH (median, 0.0 vs 4.0 years). STAR-Arg272Cys or -Met225Thr was identified only in NCLCAH (8/11, 72.7%). CONCLUSIONS: We demonstrated the relative proportions and clinical and molecular characteristics of NCLCAH and CLCAH in Japan. These criteria for NCLCAH correspond to all previously published cases and our cases whose masculinization of the external genitalia, ability of mineralocorticoid production, and onset of PAI were described.
引用
- Ishii T, Tajima T, Kashimada K, et al. Clinical Features of 57 Patients with Lipoid Congenital Adrenal Hyperplasia: Criteria for Nonclassic Form Revisited. J Clin Endocrinol Metab. 2020. PMID: 32835366. doi:10.1210/clinem/dgaa557
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。